# PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS

Source: https://onco.cc/trials/nct07761533/  
OnCo record `nct07761533` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PBSS1113 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Chaser Therapeutics, Inc., now recruiting.

## Summary

PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS is a phase 1/2 interventional study registered as NCT07761533 by Chaser Therapeutics, Inc., with 29 participants planned, started 2025-09-08 and due to reach its primary completion in 2027-09. Interventions recorded: PBSS1113.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07761533
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Dose-Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PBSS1113 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Sponsor: Chaser Therapeutics, Inc.
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT07761533: https://clinicaltrials.gov/study/NCT07761533

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)

---
JSON: https://onco.cc/api/v1/entities/nct07761533.json